Members |
targetComponentId |
Other therapeutic cystoscopy NOS |
Transurethral cystoscopy (procedure) |
Other therapeutic endoscopic operation on esophagus using rigid esophagoscope NOS |
Rigid esophagoscopy |
Other therapeutic endoscopic operations on esophagus using rigid esophagoscope |
Rigid esophagoscopy |
Other therapeutic fiberoptic endoscopic operation on esophagus NOS |
Endoscopy of esophagus |
Other therapeutic fiberoptic endoscopic operations on esophagus |
Endoscopy of esophagus |
Other thiobarbiturate poisoning |
Poisoning by thiobarbiturate |
Other tick-borne hemorrhagic fever |
Tick-borne hemorrhagic fever |
Other transfusion reaction |
Blood transfusion reaction |
Other transitory neonatal electrolyte disturbance |
Perinatal endocrine and metabolic disorders |
Other transitory neonatal endocrine and metabolic problem |
Perinatal endocrine and metabolic disorders |
Other transitory neonatal endocrine or metabolic disturbance NOS |
Perinatal endocrine and metabolic disorders |
Other umbilical cord complication, NEC |
Umbilical cord complication |
Other unspecified cystoscopic destruction of bladder lesion |
Flexible cystoscopy and cystodiathermy to bladder lesion (procedure) |
Other unspecified derangement of medial meniscus, NEC |
Derangement of medial meniscus |
Other uterine inertia, NEC |
Uterine inertia |
Other venous complication of pregnancy or puerperium, NEC |
Venous complication of pregnancy and/or puerperium (disorder) |
Other viral disease contact |
Exposure to viral disease |
Other viral disease contact |
Exposure to viral disease |
Other vomiting complicating pregnancy, NEC |
Vomiting of pregnancy |
Otocolobus manul |
Felis manul |
Otopalatodigital syndrome |
Otopalatodigital syndrome spectrum disorder |
Otto's pelvis |
Intrapelvic protrusion of acetabulum |
Otus asio |
Megascops asio (organism) |
concept périmé |
Outdated component (foundation metadata concept) |
Outer half of dentin |
Outer third of dentin |
Ovary TNM finding |
American Joint Committee on Cancer allowable value |
Over the counter nicotine replacement therapy |
Nicotine replacement therapy |
Over the counter nicotine replacement therapy |
Nicotine replacement therapy |
Over the counter nicotine replacement therapy |
Nicotine replacement therapy |
Overdose of sodium valproate |
Valproate overdose |
Overdose of sodium valproate of undetermined intent |
Valproate overdose |
Overeating associated with other psychological disturbances |
Psychogenic overeating |
Overexposure to radioactive isotope NOS |
Overexposure to radioactive isotopes |
Overgranulating secondary intention surgical wound |
Over-granulating secondary intention surgical wound (finding) |
Overlapping malignant neoplasm of ill-defined site |
Malignant neoplastic disease (disorder) |
Overriding right ventriculoarterial valve |
Pulmonary valve overriding ventricular septum (disorder) |
Ovis musimon |
Ovis aries |
Ovotestis |
Ovotesticular disorder of sex development |
Ovula Nabothi |
Retention cyst |
Oxacillin sodium 250mg/5mL powder for oral solution |
Product containing precisely oxacillin 50 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Oxford Knee Score version 1.0 score |
Oxford Knee Score using revised scoring system (observable entity) |
Oxidase |
Oxidase |
Oxo-acid-lyase |
Oxo-acid-lyase |
Oxybuprocaine 0.4% eye drops |
Oxybuprocaine only product |
Oxybuprocaine hydrochloride 0.4% conventional release eye drops |
Oxybuprocaine only product |
Oxybuprocaine hydrochloride 0.4% single-use eye drops |
Oxybuprocaine only product |
Oxybutynin 3.9mg/day transdermal system |
Product containing precisely oxybutynin 162 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
Oxybutynin hydrochloride 15mg m/r tablet |
Oxybutynin only product in oral dose form |
Oxybutynin hydrochloride 15mg prolonged-release oral tablet |
Oxybutynin only product in oral dose form |
Oxycodone hydrochloride 160mg m/r tablet |
Product containing only oxycodone in oral dose form (medicinal product form) |
Oxycodone hydrochloride 160mg prolonged-release oral tablet |
Product containing only oxycodone in oral dose form (medicinal product form) |
Oxygenase |
Oxygenase |
Oxymetazoline hydrochloride 0.025% nose drops |
Oxymetazoline hydrochloride 250 microgram/mL nasal solution |
Oxymetazoline hydrochloride 0.05% eye drops |
Oxymetazoline hydrochloride 500 microgram/mL eye solution |
Oxymetazoline hydrochloride 0.05% nose drops |
Oxymetazoline hydrochloride 500 microgram/mL nasal solution |
Oxymorphone 10mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 10mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 20mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 20mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 40mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 40mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 5mg m/r tablet |
Oxymorphone only product in oral dose form |
Oxymorphone 5mg prolonged-release oral tablet |
Oxymorphone only product in oral dose form |
Oxytocic preparation |
Medicinal product acting as oxytocic (product) |
Oxytocin 10unt infusion solution 1mL vial |
Product containing precisely oxytocin 10 unit/1 milliliter conventional release solution for injection (clinical drug) |
Oyster - dietary |
Oyster (substance) |
PEG-intron redipen 120micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 120 microgram powder for solution for injection pen |
PEG-intron redipen 150micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 150 microgram powder for solution for injection pen |
PEG-intron redipen 50micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 50 microgram powder for solution for injection pen |
PEG-intron redipen 80micrograms powder+sterile water 0.5mL |
Interferon alfa-2b (as peginterferon alfa-2b) 80 microgram powder for solution for injection pen |
PIE syndrome |
Löffler's syndrome (disorder) |
Packing - action |
Insertion - action (qualifier value) |
Paclitaxel 1mcg/mm drug eluting stent |
Paclitaxel 1 microgram/mm2 drug eluting stent (product) |
Painful ejaculation |
Painful ejaculation |
Palatal flap |
Flap (substance) |
Palatoplasty |
Uvulopalatopharyngoplasty |
pamidronate disodique 3 mg/mL, fiole de 5 mL de concentré pour perfusion |
Product containing precisely disodium pamidronate 3 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Pancreas excision |
Pancreatectomy |
Pancrelipase, amylase:lipase 183.49mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 184.84mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 210.33mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 278.72% capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 312.17mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 346.86mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 4500unit capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 62.81% |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 62.81% capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pancrelipase, amylase:lipase 94.3mg capsule |
Amylase and pancrelipase and triacylglycerol lipase only product |
Pantoprazole sodium 40mg injection |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Pantoprazole sodium 40mg m/r tablet |
Pantoprazole (as pantoprazole sodium) 40 mg gastro-resistant oral tablet |
Pantoprazole sodium 40mg powder |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Pantoprazole sodium 40mg/vial powder for injection |
Pantoprazole (as pantoprazole sodium) 40 mg powder for solution for injection vial |
Papain specific extract |
Product containing papain (medicinal product) |
Papaya - dietary |
Papaya (substance) |
Paphosia adorabilis |
Lophornis adorabilis (organism) |
Papillary cystadenoma, borderline malignancy |
Papillary cystadenoma, borderline malignancy |
Papillary mucinous cystadenoma, borderline malignancy |
Papillary mucinous cystadenoma, borderline malignancy |
Papillary serous cystadenocarcinoma |
Serous cystadenocarcinoma |
Papillary serous cystadenoma, borderline malignancy |
Serous papillary cystic tumour of borderline malignancy |
Papilloma, no International Classification of Diseases for Oncology subtype (except papilloma of bladder M-81201) |
Benign papilloma (morphologic abnormality) |
Para-aminophenol derivative anti-inflammatory agent |
Para-aminophenol derivative |